#Sebetralstat

Rare Disease Advisor

@rarediseaseadvisor.bsky.social

1 month ago

New Treatment Approaches on the Horizon for Patients With HAE Three therapies—berotralstat, sebetralstat, and lonvo-z—could offer hope to those who suffer from HAE attacks, which can be life-threatening.

Three therapies—#Berotralstat, #Sebetralstat, and #LonvoZ—could offer hope to those who suffer from #HAE attacks, which can be life-threatening.

Read the full feature here: https://bit.ly/3LJb9WX

#RareDisease #HereditaryAngioedema

Angioedema News

@angioedemanews.bsky.social

3 months ago

#HAE #HereditaryAngioedema #HaeWarrior #HAEKids #PediatricHAE #RareDisease #RareDiseaseCommunity #ChronicIllness #OnDemandTreatment #Ekterly #Sebetralstat ##RareButNotAlone #CaregiverLife #ClinicalTrials #BioNews #AngioedemaNews

Rare Disease Advisor

@rarediseaseadvisor.bsky.social

4 months ago

Pediatric HAE Study Supports Safety and Early Relief With Sebetralstat Sebetralstat provides comparable drug exposure and early symptom relief in children aged 2 to 11 years with HAE as that seen in older patients.

#ACAAI25: #Sebetralstat appears to be a safe, effective, and easy-to-use oral treatment for acute #HAE attacks in children aged 2 to 11 years, with drug exposure and early symptom relief comparable with older patients.

Read more: https://bit.ly/4oyKrOL

#RareDisease #KONFIDENTKID #MedSky

Angioedema News

@angioedemanews.bsky.social

5 months ago

#HAE #HereditaryAngioedema #Ekterly #Sebetralstat #OralHAETreatment #OnDemandTherapy #ChronicIllness #RareDisease #Angioedema #PatientEmpowerment #SwellingRelief #SpoonieLife #HAECommunity #KalVista #BioNews #AngioedemaNews

Angioedema News

@angioedemanews.bsky.social

5 months ago

If approved this October, patients may soon have a new needle‑free option to manage swelling
episodes quickly and confidently.

#HereditaryAngioedema #HAE #RareDisease #Sebetralstat #Ekterly #OrphanDrug #KalVista #OnDemandTherapy #BioNews #AngioedemaNews

Angioedema News

@angioedemanews.bsky.social

6 months ago

Already approved in the US and UK (as Ekterly), this new option could make treating attacks easier, faster, and injection-free for people 12 and up.

#HAE #HAEAwareness #HereditaryAngioedema #Sebetralstat #ChronicIllness #RareDisease #AngioedemaNews #Bionews

Angioedema News

@angioedemanews.bsky.social

7 months ago

#Angioedema #AngioedemaTreatment #HAE #RareDisease #Sebetralstat #AngioedemaNews #Bionews

pharmaphorum

@pharmaphorum.bsky.social

8 months ago

KalVista bags FDA approval for delayed oral HAE drug KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.

#KalVistaPharma has finally received FDA approval for its oral kallikrein inhibitor #sebetralstat, becoming the first treatment in the US that can provide oral, on-demand treatment of hereditary angioedema (#HAE) attacks.

pharmaphorum.com/news/kalvist...